The surveillance study of nausea and vomiting associated with transcatheter arterial chemoembolization for hepatocellular carcinoma

The surveillance study of nausea and vomiting associated with transcatheter arterial chemoembolization for hepatocellular carcinoma - The surveillance study of nausea and vomiting associated with transcatheter arterial chemoembolization for hepatocellular carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005839

Enrollment

300

Registered

2011-07-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

control NK1 receptor antagonist 5-HT3 receptor antagonist

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients who are diagnosed as hepatocellular carcinoma and candidates for transcatheter arterial chemoembolization

Exclusion criteria

Exclusion criteria: (1)Child Pugh score C (2)hepatic encephalopathy II or more (3)total bilirubin 3.0mg/dL or more (4)the patients who are treated for neuropsychiatric disorder (5)the patients who takes anti-anxiety agent (6)the patients who takes Pimozide (7)the patients who are judged to be ineligible for entry of this study

Design outcomes

Primary

Measure	Time frame
The primary outcomes of this study is the incidence of nausea and vomiting without antiemetic drugs and the rate of symptom amelioration by antiemetic drugs after transcatheter arterial chemoembolization for hepatocellular carcinoma.	—

Countries

Japan

Contacts

Public ContactTakayuki Yakushijin

Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology

yakushijin@gh.med.osaka-u.ac.jp06-6879-3621

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026